Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: Analysis of trends over time

Cancer

Volumn 118, Issue 23, 2012, Pages 5768-5776

  Scosyrev, Emil ^a   Wu, Guan ^a   Mohile, Supriya ^a   Messing, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

incidence rates; metastatic disease; prostate cancer; prostate specific antigen; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RACE; RISK ASSESSMENT; SYMPTOMATOLOGY; TREND STUDY; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; SEER PROGRAM;

EID: 84869502190     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27503     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Kopec JA, Goel V, Bunting S, et al. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol. 2005; 174: 495-499. (Pubitemid 40981582)
3. Weinmann S, Richert-Boe K, Glass AG, et al. Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control. 2004; 14: 133-138. (Pubitemid 38445359)
4. Weinmann S, Richert-Boe K, Van Den Eeden SK, et al. Screening by prostate-specific antigen and digital rectal examination in relation to prostate cancer mortality. Epidemiology. 2005; 16: 367-376. (Pubitemid 40586713)
5. Agalliu I, Weiss NS, Lin DW, et al. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control. 2007; 18: 931-937. (Pubitemid 47237956)
6. Marcella SW, Rhoads GG, Carson JL, et al. Prostate-specific antigen screening and mortality from prostate cancer. J Gen Intern Med. 2008; 23: 248-253.
7. Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer. Arch Intern Med. 2006; 166: 38-43.
8. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
9. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P,. Randomized prostate cancer screening trial: 20 years follow-up [serial online]. BMJ. 2011; d1539.
10. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004; 59: 311-318. (Pubitemid 38509764)
11. Andriole GL, Crawford D, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
12. Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011; 29: 355-361.
13. Lacy S,. AUA Response to 2011 US Preventive Services Task Force Draft Recommendations on Prostate Cancer Testing. Available from: http://www.auanet. org/content/health-policy/government-relations-and-advocacy/in-the-news/ aua-response-to-uspstf.cfm. Accessed January 4, 2012.
14. Schroder FH,. Stratifying risk the US Preventive Services Task Force and prostate-cancer screening. N Engl J Med. 2011; 365: 1953-1955.
15. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G,. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality [published online ahead of print October 17, 2011]. Cancer. 2011.
16. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE,. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 29: 1736-1743.
17. Scosyrev E, Messing J, Noyes K, Veazie P, Messing E,. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview [published online ahead of print April 2, 2010]. Urol Oncol. 2010.
18. Shambaugh EM, Ries LG, Young JL,. Extent of Disease. New 4-digit Schemes. Codes and Coding Instructions. Bethesda, MD: SEER Program, National Cancer Institute; 1983. Available from: http://seer.cancer.gov/tools/codingmanuals/ historical.html. Accessed December 29, 2011.
19. Shambaugh EM, Gloeckler Ries L, Young JL, et al. SEER Extent of Disease 1988. Codes and Coding Instructions. Bethesda, MD: SEER Program, National Cancer Institute; 1988. Available from: http://seer.cancer.gov/tools/codingmanuals/ historical.html. Accessed December 29, 2011.
20. Fritz A, ed. SEER Extent of Disease. Codes and Coding Instructions, 3rd ed. Bethesda, MD: SEER Program, National Cancer Institute; 1998. Available from: http://seer.cancer.gov/tools/codingmanuals/historical.html. Accessed December 29, 2011.
21. Johnson CF, ed. The SEER Program Coding and Staging Manual 2004, Appendix C. NIH Publication no. 04-5581. Bethesda, MD: SEER Program, National Cancer Institute; 2004.
22. Greenland S, Rothman KJ,. Introduction to Stratified Analysis. In, Rothman KJ, Greenland S, Lash TL,. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008: 265-268.
23. Gong Z, Agalliu I, Lin DW, et al. Obesity is associated with increased risk of prostate cancer metastases and death after initial cancer diagnosis in middle-aged men. Cancer. 2007; 109: 1192-1202. (Pubitemid 46435400)
24. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997; 79: 235-246.
25. Boustead G, Edwards SJ,. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU Int. 2007; 99: 1383-1389.
26. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7: 472-479. (Pubitemid 43779173)
27. DeAntoni E, Crawford ED, Stone NN, et al. Prostate Cancer Awareness Week, 1992: a summary of key findings. Clin Invest Med. 1993; 16: 448-457. (Pubitemid 24111959)
28. Chambers CC,. Prostate cancer and prostate-specific antigen: facts, figures, and commentary. J Insur Med. 1993; 25: 336-340.
29. Catalona JW, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991; 324: 1156-1161.
30. Mettlin C,. Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project. Clin Invest Med. 1993; 16: 440-447. (Pubitemid 24111958)